Vaxcyte stock gains 1.36 percent as shares close at USD 58.92

Vaxcyte, Inc. (US92242T1016) stock closed at USD 58.92 on Nasdaq on September 21, 2026, a gain of 1.36 percent from the prior close. The latest quoted session provides the clearest dated market signal for PCVX as the company remains a clinical-stage vaccine developer.

Shares finish at USD 58.92

The September 21, 2026 closing price of USD 58.92 and the 1.36 percent daily increase are reported in the PCVX market snapshot. The quotation was recorded at 4:00 p.m. EDT, while the after-hours indication stood at USD 58.92 at 4:43 p.m. EDT, leaving the displayed after-hours price unchanged.

For investors, the percentage move matters less than the level at which the shares finished: PCVX remained below the 52-week high shown in the available market data. The dated quote therefore gives the article a precise reference point without mixing Nasdaq pricing with another trading venue.

Clinical pipeline drives valuation

Vaxcyte's investment case is tied to the development of vaccine candidates rather than an established commercial revenue stream. The market snapshot identifies PCVX as Vaxcyte, Inc., but does not provide a current reporting-period revenue, earnings, margin, guidance, or analyst price target figure.

The most concrete comparison available for September 21, 2026 is the 1.36 percent session change against the prior Nasdaq close. That move places the stock's latest performance in a measurable daily context, while the USD 58.92 closing level remains the key price reference for the company.

Nasdaq quote anchors PCVX

PCVX's primary reference venue is Nasdaq, and the September 21, 2026 quote is stated in USD. The stock finished at USD 58.92, with the market snapshot also recording zero change in the after-hours indication at 4:43 p.m. EDT.

More news and analyses on Vaxcyte stock